
Amsterdam, Netherlands : 1 - 3 February 2018
Evading cell death is a hallmark of cancer cells, which contributes to tumour growth and therapeutic resistance. But cancer cells also highjack mechanisms like protective autophagy or senescence to promote tumour growth. Cell death is an important determinant of the immune response to cancer, which may either increase the antitumour effect or promote tumour growth.
The conference will cover exciting new insights into this highly-relevant field, so please join us in Amsterdam to be stimulated by the latest research updates!
With its translational character, the conference has been designed for basic and translational cancer scientists, as well as oncologists who are interested in the multifaceted role of cell death in cancer.
We strongly encourage early-stage basic cancer researchers and medical oncologists to present their work to the international community. There will be plenty of opportunities for interaction with some of the top experts in the field, including Round Table Discussions. We anticipate an inspiring informal atmosphere to share research findings, and to establish or strengthen collaborations.
Mechanisms and regulation of classical apoptotic and non-classical modes of cell death
Mechanistic insight into autophagy and senescence
Therapeutic strategies modulating cell death in cancer cells
Impact of cell death on immune responses to cancer and cancer therapies
Scientific Programme Committee: Simone Fulda, Verena Jendrossek (chair), Jan Paul Medema
Bursary application deadline:
10 November 2017
Abstract submission deadline:
20 November 2017
Registration deadline:
05 January 2018
De Rode Hoed, a former hidden church in the centre of Amsterdam.

This is considered an out of date browser. This website has been developed with modern browsers in mind to allow it to display at its best in a wide variety of viewing situations - including mobile viewing. But we haven't supported older browsers like IE8. Please upgrade to the latest version of Internet Explorer - or try Mozilla Firefox or Google Chrome. Both are excellent browsers.
Thank you.